Diagnostic N-terminal midfragment of Osteocalcin (N-MID OC) antibodies (anti-N-terminal midfragment of Osteocalcin, anti-N-MID OC) and antigens (recombinant N-terminal midfragment of Osteocalcin (N-MID OC) protein) for Metabolic diseases N-MID OC detection in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT.
Cat:GMP-h-N-MID-OC
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Genemedi produces core diagnostic ingredients for test of Metabolic diseases (osteoporosis) and related syndrome. GeneMedi offers paired diagnostics grade N-terminal midfragment of Osteocalcin (N-MID OC) antibodies (monoclonal antibody, mab) and antigens for Metabolic diseases (osteoporosis) rapid test kit of N-terminal midfragment of Osteocalcin (N-MID OC) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Metabolic diseases (osteoporosis ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.
Genemedi produces core diagnostic ingredients for test of Metabolic diseases (osteoporosis) and related syndrome. GeneMedi offers paired diagnostics grade N-terminal midfragment of Osteocalcin (N-MID OC) antibodies (monoclonal antibody, mab) and antigens for Metabolic diseases (osteoporosis) rapid test kit of N-terminal midfragment of Osteocalcin (N-MID OC) testing in standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for Metabolic diseases (osteoporosis ) test are suitable for in functional ELISA, and other immunoassays in dignostics.The antibodies can act as a capture antibody and detection antibody. The antigens can be used as positive control.The procollagen type I N-terminal propeptide (P1NP) and osteocalcin (OC) are the the most sensitive markers of bone formation rate. Although labile, assay of intact osteocalcin (iOC) is established as the standard assay for evaluating osteoblastic function. Study examines the clinical usefulness of the newly developed immunoradiometric assay for osteocalcin (OC), which identifies the stable N-terminal midfragment of OC (N-MID OC assay). The findings suggest that N-MID OC immunoreactivity is much more stable than iOC immunoreactivity and that N-MID OC assay may be less susceptible to the OC fragments reported to accumulate in uremic serum. It may, therefore, prove more reliable than iOC assay for evaluating bone turnover, and thus for reflecting bone loss.
Product Description
Cat No. of Pruducts
GMP-h-N-MID-OC-Ag01
Product Name
Recombinant human Human N-MID OC Protein
Target
N-terminal midfragment of Osteocalcin
Alias of Target/Biomarker
Expression platform
E.coli
Isotypes
Recombinant Antigen
Bioactivity validation
N-terminal midfragment of Osteocalcin (N-MID OC) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in N-MID OC level test of Metabolic diseases (osteoporosis) and related syndrome evaluation
Tag
His
Products description
Recombinant human Human N-MID OC Protein was expressed in E.coli -based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
Standard substance, positive control, ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -86℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Previous slide
Next slide
Cat No. of Pruducts
GMP-h-N-MID-OC-Ab01, GMP-h-N-MID-OC-Ab02
Product Name
Anti-human Human N-MID OC mouse monoclonal antibody (mAb)
Target
N-terminal midfragment of Osteocalcin
Alias of Target/Biomarker
BGLAP, BGP, OC, OCN
Expression platform
Hybridoma
Isotypes
Mouse IgG
Bioactivity validation
Human N-terminal midfragment of Osteocalcin (N-MID OC) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other N-terminal midfragment of Osteocalcin (N-MID OC) antibodies in N-MID OC level test of Metabolic diseases (osteoporosis) and related syndrome evaluation.
Tag
mFc
Products description
Anti-human Human N-MID OC mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other N-terminal midfragment of Osteocalcin (N-MID OC) antibodies.
Reconized/Reactive Species
Human
Purity
Purity: ≥95% (SDS-PAGE)
Application
ELISA test, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT
Formulation
Supplied as a 0.2 μM filtered solution of PBS,PH7.4.
Storage
Store at -20℃ to -87℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
Diagnostic antibodies and antigens for cancer detection - TG, CA-125, SCC Ag, PIVKA-Ⅱ, ProGRP, Calcitonin, NSE, CA-724, HE4, CA15-3, FER, CYFRA21-1, HER2, HSP90α, S100B, CEA, AFP, sFlt-1, PSA, hEGF, TFF2, TFF3, CA199, CA50, TK1
Regardless of the advances in the cancer therapy, delayed symptoms and lack of successful diagnosis of cancer at early stage increased the death rate. Tumor-associated antigens (TAAs) and their antibodies have been identified as potential markers in cancer diagnosis and determination. TAAs and their antibodies-based detection of cancer have the advantages such as low-cost, and simple access, which attracted much attention for early cancer detection. For several reasons, tumor marker itself is typically insufficient to analyze disease conditions. Because, maximum number of markers have been produced by both normal and cancer cells. Several cancers such as anal, breast, ovaries, testicles, colon, endometrial, peritoneal, fallopian tube, gallbladder, gastric, liver, lung, neuroendocrine, pancreatic, prostate, renal, cervix, stomach and thyroid cancer, bronchopulmonary dysplasia, hepatitis, hematological malignancies, hemochromatosis, hypercalcemia, osteoporosis, Parget’s diseases and so on have been identified using specific marker. Detecting the quantity of marker proteins from different samples may benefit from ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
